Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapies employing platelet aggregation drugs

A drug and composition technology, applied in the field of combination therapy using platelet aggregation drugs, can solve problems such as non-use

Inactive Publication Date: 2007-08-08
MEDICURE INT INC
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, currently there are no combination therapies using pyridoxal-5'-phosphate or pyridoxal-5'-phosphate-related compounds with antiplatelet agents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapies employing platelet aggregation drugs
  • Combination therapies employing platelet aggregation drugs
  • Combination therapies employing platelet aggregation drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0104] Example 1-Pyridoxal-5-phosphate is used to reduce the effect of myocardial ischemic injury after coronary surgery

[0105] Methods - Study overview: 60 patients undergoing percutaneous coronary intervention (PCI) were randomly selected in 4 centers and treated with P5P or placebo in a 2:1 double-blind manner. Inclusion criteria required prior identification of a single vessel injury for non-emergency PCI and identification of ≥1 of the following clinical features that identify a high risk of procedure-related ischemic complications (Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ , Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-251; The ESPRIT Investigators. Noveldosing regimen of eptifibatide in planned coronary: stenta implantation randomised, placebo-controlled trial. Lancet 2000;356:2037-2044): Presence of acute coronary syndrome (chest pain within 48 hours of ...

Embodiment 2

[0120] Example 2-Pyridoxal-5'-phosphate combined with aspirin for reducing myocardial ischemic injury after coronary surgery

[0121] Method: Analysis Research data of Example 1. Of the 60 patients described in Example 1, 35 patients received adjuvant therapy with acetylsalicylic acid [82 mg (6 patients)] and 325 mg (29 patients) in addition to P5P therapy.

[0122] result: In patients treated with P5P and ASA, the secondary endpoint of maximum perioperative CK-MB levels was reduced from 3.41 ng / ml (placebo and ASA) to 2.09 ng / ml (P5P and ASA; Table 4).

[0123] Table 4

[0124] combination therapy

[0125] in conclusion: Combination P5P and ASA therapy was associated with a significant reduction in peak perioperative CK-MB elevation and a reduction in perioperative infarct volume.

Embodiment 3

[0126] Example 3-Pyridoxal-5'-phosphate combined with epifetide (Integrillin) is used to reduce the effect of myocardial ischemia injury after coronary artery surgery

[0127] method: The study data of Example 1 were analyzed. Of the 60 patients described in Example 1, 19 patients received adjuvant therapy with Epifetide in addition to P5P therapy.

[0128] result: The secondary endpoint of maximum perioperative CK-MB levels was reduced from 3.40 ng / ml (placebo and epifetide) to 1.36 ng / ml (P5P and substitute).

[0129] in conclusion: Combination therapy of P5P and epifetide was associated with a significant reduction in peak perioperative CK-MB elevation (Table 4), and a reduction in perioperative infarct volume.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides pharmaceutical compositions comprising a platelet aggregation inhibitor and a compound selected from pyridoxal-5'-phosphate, a pyridoxal-5'-phosphate related compound or a pharmaceutically acceptable salt thereof and methods for using a platelet aggregation inhibitor and a compound selected from pyridoxal-5'-phosphate, a pyridoxal-5'-phosphate related compound or a pharmaceutically acceptable salt thereof, for inhibiting platelet aggregation, for treating diseases that arise from prothrombotic and thrombotic states in which the coagulation cascade is activated and for reducing the risk of cardiovascular disease or cerebrovascular disease.

Description

technical field [0001] The present invention relates to a pharmaceutical composition and its use for treating cardiovascular diseases. In particular, the invention relates to the use of combination therapy with platelet aggregation drugs. Background technique [0002] The role of platelets in the pathophysiology of atherosclerotic disease and thrombotic events is well known. Long-term prophylactic use of antiplatelet drugs that inhibit platelet aggregation has been shown to be beneficial in preventing ischemic stroke, myocardial infarction, unstable angina, peripheral arterial disease, need for vascular bypass surgery or angioplasty, and vascular death in patients, Said patients are at increased risk of these events and include those with established atherosclerosis or a history of arterial thrombosis. [0003] Currently, many antiplatelet drugs are widely available and their combination therapy has been and continues to be studied. Most antiplatelet drugs have side effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61P7/02A61K31/675A61K31/616A61K31/4365
CPCA61K31/675A61K45/06A61K31/616A61K31/4415A61K31/4365A61P43/00A61P7/02A61P9/00A61P9/04A61P9/10A61P9/12A61K2300/00
Inventor 阿尔贝特·弗里森
Owner MEDICURE INT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com